DiaMedica Therapeutics, Inc.

  • Home
  • Our Focus
    • Overview
    • Literature & Publications
  • Pipeline
    • Overview
    • Acute Ischemic Stroke
    • IgA Nephropathy
    • African Americans with CKD
  • Clinical Trials
    • Overview
    • Acute Ischemic Stroke
    • Chronic Kidney Diseases
  • ReMEDy2
    • Overview
    • About ReMEDy2
    • Stroke Disease
    • For Physicians
    • Trial Locations
  • About DiaMedica
    • Overview
    • Leadership
    • Careers
    • Contact
  • Investors Relations
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Data
    • Analyst Coverage
    • Financial Reports & SEC Filings
    • Governance
    • Resources

Press Releases

Investors Relations

Investors Relations

  • Overview
  • Press Releases
  • Events & Presentations
  • Stock Data
    • Nasdaq Quote
    • Charts
    • Historical Data
  • Analyst Coverage
  • Financial Reports & SEC Filings
    • SEC Filings
    • Annual Reports
    • Tax Information (PFIC)
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • Investor Contact
    • FAQ
    • Share Consolidation Instructions
    • Email Alerts
Mar 09, 2020 8:10am EDT

DiaMedica Therapeutics to Participate at 32nd Annual ROTH Conference on March 15-17, 2020

Feb 13, 2020 4:35pm EST

DiaMedica Therapeutics Announces Closing of $8.5 Million Public Offering of Common Shares

Feb 11, 2020 7:15am EST

DiaMedica Announces Pricing of Public Offering of Common Shares

Dec 17, 2019 4:14pm EST

DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease

Nov 13, 2019 4:12pm EST

DiaMedica Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update

Nov 06, 2019 4:04pm EST

DiaMedica Therapeutics to Report Third Quarter 2019 Financials and Provide a Business Update November 14, 2019

Nov 05, 2019 4:04pm EST

DiaMedica Therapeutics to Participate in 10th Annual Craig-Hallum Alpha Select Conference

Oct 14, 2019 7:42am EDT

DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease

Sep 06, 2019 9:00am EDT

DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019

Sep 03, 2019 4:15pm EDT

DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference

  • Previous
  • 1…
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2023 DiaMedica Therapeutics, Inc. All Rights Reserved.
Twitter LinkedIn
Privacy Policy Disclaimer Sitemap